Bragar Eagel & Squire, P.C. is Investigating Nabriva Therapeutics plc (NBRV) on Behalf of Stockholders and Encourages NBRV Investors to Contact the Firm
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Nabriva Therapeutics plc (NASDAQ: NBRV). Our investigation concerns whether Nabriva has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 30, 2019, Nabriva disclosed receipt of a Complete Response Letter (“CRL”) from the FDA for the company’s New Drug Application (“NDA”) seeking marketing approval of CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva advised investors that “[t]he CRL requests that Nabriva address issues related to facility inspections and manufacturing deficiencies at one of Nabriva’s contract manufacturers prior to the FDA approving the NDA.”
On this news, Nabriva’s share price fell by more than 27%, closing at $2.17 on May 1, 2019.
If you purchased or otherwise acquired Nabriva shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Nabriva please go to http://www.bespc.com/nbrv/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.